EUVIMEDEUVIMED entdecken
Fallbericht

Treatment of facial reactive B‐cell rich lymphoid proliferation with dapsone

Makoto Sugaya iD, Akari Nagashima, Risae Nakamura, Megumi Yano, Takashi Morita, Yasuko Niijima, Tomonori Takekoshi, Naoko Kanda iD, Masaru Tanaka iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17614 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Makoto Sugaya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, International University of Health and Welfare, Chiba, Japan. Hauptthemen laut MEDLINE: Dapsone, Pseudolymphoma, Facial Dermatoses. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactive B‐cell rich lymphoid proliferation (rB‐LP), once called pseudolymphoma, is a benign lymphoproliferative disorder, which is histologically characterized by dense dermal infiltrate forming reactive germinal centers with tingible body macrophages. The disease frequently involves the face, scalp, and ear lobes. Treatment includes topical or intralesional steroids, surgical resection, ultraviolet therapy, laser treatment, and radiation therapy. Cases with multiple skin lesions, however, are difficult to treat with local therapies. Oral steroids are sometimes used, although the variety of side effects and recurrence during decreases in the dosage are the main problem. Here we report seven cases of rB‐LP treated with dapsone, which has anti‐inflammatory effect. Although the number of cases was limited, there was a trend that patients with multiple nodules on both sides of the face showed a good response. The limitations of this study include it being a case series from a single institute, and possible effects of topical steroids. We can, however, safely say that dapsone may be useful in some patients with rB‐LP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DapsonePseudolymphomaFacial DermatosesHumansMaleFemaleMiddle AgedAdultAgedTreatment OutcomeB-LymphocytesFace

Stichwörter der Autor:innen

dapsoneleukotrieneslymphoid proliferationprotozoal microbiotatingible body macrophages

Substanzen

Dapsone

Autor:innen und Institutionen

  • Department of Dermatology, International University of Health and Welfare, Chiba, Japan.
  • Department of Dermatology, Shinmatsudo Central General Hospital, Chiba, Japan.
  • Department of Dermatology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.

ORCID-Profile: Makoto Sugaya, Naoko Kanda, Masaru Tanaka

Zitieren

APA

Sugaya, M., Nagashima, A., Nakamura, R., Yano, M., Morita, T., Niijima, Y., Takekoshi, T., Kanda, N., & Tanaka, M. (2025). Treatment of facial reactive B‐cell rich lymphoid proliferation with dapsone. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17614

Vancouver

Sugaya M, Nagashima A, Nakamura R, Yano M, Morita T, Niijima Y, et al. Treatment of facial reactive B‐cell rich lymphoid proliferation with dapsone. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17614

BibTeX
@article{Sugaya2025,
  author = {Sugaya, Makoto and Nagashima, Akari and Nakamura, Risae and Yano, Megumi and Morita, Takashi and Niijima, Yasuko and Takekoshi, Tomonori and Kanda, Naoko and Tanaka, Masaru},
  title = {Treatment of facial reactive B‐cell rich lymphoid proliferation with dapsone},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17614}
}
Kostenlos starten →